Emerging studies suggest this peptide, a dual agonist targeting both GLP-1 and GIP , may offer a notable development for obesity management . Preliminary patient trials have shown impressive reductions in visceral tissue, possibly exceeding other obesity therapies . Nevertheless , additional click here assessment is required to thoroughly understan